Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Cornerstone Therapeutics Inc. (NASDAQ:CRTX) fell $1.37 (21%) to $5.10 on Thursday after FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure (CHF) and euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH). The committee voted 8-0 against the CHF indication and 5-3 against the SIADH indication. The product has an Oct. 29 PDUFA date.

The stock lost $1.08 (18%) to $5.06 on the week.

InterMune Inc. (NASDAQ:ITMN) gained $1.06 (13%) to $9 last week after announcing France's Comite Economique des Produits de Sante (CEPS) will reimburse for use of Esbriet pirfenidone in idiopathic pulmonary fibrosis (IPF).

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB) fell $0.87 (25%) to $2.64 on Tuesday after announcing FDA issued a complete response letter for Lymphoseek tilmanocept for use in intraoperative lymphatic imaging. According to Navidea, the agency raised issues related to third party contract manufacturers. The company said the letter did not raise concerns about efficacy or safety.

Navidea lost $0.75 (21%) to $2.82 for the

Read the full 1680 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers